Filing Analysis
Z Squared Inc. (formerly Coeptis Therapeutics) entered into a binding LOI to acquire Skycore Digital LLC for up to $22 million in preferred stock and announced a total turnover of its executive leadership and board following a merger. The company also disclosed multiple equity-based compensation agreements with various consulting and investor relations firms.
Red Flags
- Complete turnover of the Board of Directors and executive management team in a single event.
- Significant pivot in business model implied by the acquisition of data center assets (Skycore) by a company formerly named Coeptis Therapeutics.
- High volume of equity-based compensation for investor relations and marketing services, which can be dilutive and sometimes associated with stock promotion.
- Multiple 8-K items (1.01, 3.02, 5.02) filed simultaneously indicating complex corporate restructuring.
Key Facts
- Binding LOI to acquire 100% of Skycore Digital LLC for an initial $18 million in Series B Convertible Preferred Stock, potentially increasing to $22 million based on power capacity milestones.
- The Series B Preferred Stock features an 8% cash or 10% PIK dividend and a mandatory redemption on the seventh anniversary of closing.
- Complete resignation of all prior directors and officers effective April 27, 2026, following a merger with Z Squared Opco, Inc.
- Appointment of David Halabu and Michelle Burke as Co-CEOs and Brian Cogley as CFO.
- Issuance of 200,000 shares to Group 10 Holdings and up to 566,000 shares to Moneta Advisory Partners for consulting and IR services.
- Additional share issuances for IR services to MZHCI, LLC ($100,000 value) and Retail Sparks ($75,000 value).
Coeptis Therapeutics Holdings, Inc. completed a reverse merger with Z Squared Inc. on April 24, 2026, resulting in a change of control, a name change to Z Squared Inc., and a ticker change to ZSQR. The transaction involved a complete turnover of the board and executive management, and the spin-off of legacy biopharmaceutical assets to pre-merger shareholders.
Red Flags
- Reverse merger structure, which is a common method for private companies to bypass the traditional IPO process.
- Complete turnover of management and the board of directors.
- Complex pre-merger asset reorganization and pro-rata dividend distribution to legacy shareholders.
- Significant dilution for legacy COEP shareholders, who now hold a minority stake in the new entity.
Key Facts
- Merger completed on April 24, 2026, with Z Squared Inc. (Wyoming) becoming a wholly owned subsidiary of the registrant.
- The registrant issued 43,877,497 shares of common stock to Z Squared stockholders as merger consideration.
- Total post-merger shares outstanding are 51,431,493, with Z Squared stockholders owning approximately 85% of the company.
- The company changed its name to Z Squared Inc. and its ticker symbol from 'COEP' to 'ZSQR' effective April 27, 2026.
- All previous directors and officers resigned, replaced by a new five-member board and executive team led by CEO David Halabu.
- Legacy biopharmaceutical assets (excluding GEAR Therapeutics, Inc.) were reorganized into Coeptis Holdings, Inc. (CHI) and distributed as a dividend to pre-merger stockholders.
- The transaction is accounted for as a reverse merger, with Z Squared OpCo Inc. as the accounting acquirer.
Coeptis Therapeutics Holdings, Inc. issued a press release providing supplemental information regarding its business combination with Z Squared, Inc. (NASDAQ: ZSQR). The update also includes details on a pro rata dividend distribution of Coeptis's pre-combination biopharmaceutical business to its shareholders.
Key Facts
- The company is undergoing a business combination with Z Squared, Inc. (NASDAQ: ZSQR).
- A pro rata dividend distribution is planned for Coeptis's pre-business combination biopharmaceutical assets.
- The press release was issued on April 27, 2026, to supplement previous disclosures.
- The filing was signed by Brian Cogley, Chief Financial Officer.
Coeptis Therapeutics Holdings, Inc. announced the successful completion of its business combination with Z Squared Inc. The company will transition its ticker symbol from 'COEP' to 'ZSQR' and expects to begin trading on the Nasdaq Global Market on April 27, 2026.
Key Facts
- Completed business combination with Z Squared Inc. on April 24, 2026.
- Ticker symbol change from 'COEP' to 'ZSQR' effective April 27, 2026.
- The company's shares will trade on the Nasdaq Global Market.
- New CUSIP for the common stock is 98878K108.
Coeptis Therapeutics announced that Nasdaq has conditionally approved the listing of the post-merger company's common stock on the Nasdaq Global Market. The approval is contingent upon the closing of the company's merger with Z Squared Inc., at which point the ticker will change from 'COEP' to 'ZSQR'.
Key Facts
- Nasdaq approved the listing of the post-merger entity on the Nasdaq Global Market.
- The new ticker symbol will be 'ZSQR' following the merger with Z Squared Inc.
- The approval is subject to customary conditions and the successful closing of the merger.
- The announcement was made via press release on April 7, 2026.
- The company's common stock is currently listed on the Nasdaq Capital Market.